Tesamorelin and ipamorelin:
GHRH plus ghrelin mimetic stack.

The physiologic rationale for stacking tesamorelin with ipamorelin is that GH release from pituitary somatotroph cells is regulated by two parallel stimulatory pathways, both of which can be therapeutically activated. Activating one pathway produces a GH pulse. Activating both simultaneously produces a meaningfully larger pulse — not merely additive but often multiplicative.

Pathway 1: GHRH-R (tesamorelin target). Growth hormone–releasing hormone binds GHRH-R on somatotroph cells and triggers a cyclic AMP (cAMP) signaling cascade. This cascade promotes both the transcription of new GH messenger RNA and the release of pre-formed GH from secretory vesicles. Tesamorelin is a full-length GHRH analog and activates this pathway strongly.

Pathway 2: GHS-R1a (ipamorelin target). The growth hormone secretagogue receptor type 1a, better known as the ghrelin receptor, is activated by endogenous ghrelin and by synthetic GHS peptides like ipamorelin. GHS-R1a uses a different signaling pathway — phospholipase C, diacylglycerol, and inositol trisphosphate (IP3), with downstream calcium mobilization — that converges on GH secretory vesicle release independently of the cAMP pathway.

Combined activation. When both pathways are activated simultaneously, the two signaling cascades converge on GH release through independent molecular machinery. The result is a larger GH pulse than either peptide produces alone, because the two signaling systems are not competing for the same downstream effectors. Published research on combined GHRH + GHS administration shows 2–4x greater peak GH levels than with either compound alone at comparable doses — a meaningful amplification that is the mechanistic basis for the tesamorelin ipamorelin stack.

Additionally, the two pathways interact positively in a way that goes beyond simple amplification. GHS-R1a activation by ipamorelin appears to suppress somatostatin tone (the body's GH-inhibiting hormone), which increases the magnitude of the tesamorelin-driven GHRH-R response. The stacked peptides unlock more GH release than the sum of their individual contributions.

The standard tesamorelin and ipamorelin stack protocol maintains each peptide at its monotherapy dose — the goal is to combine their effects, not to reduce either individually. Typical protocols pair 2 mg tesamorelin daily with 200–300 μg ipamorelin, often dosed 1–3 times per day.

Tesamorelin component. 2 mg subcutaneous once daily, typically morning or evening, consistent timing day to day. This matches the FDA-approved monotherapy dose and is the dose with Phase III efficacy data behind it. Reducing tesamorelin below 2 mg to "make room" for the ipamorelin addition is generally not done — the two peptides work through independent mechanisms, so there is no pharmacologic reason to cut one when adding the other.

Ipamorelin component. 200–300 μg subcutaneous per dose, 1–3 times daily. Common patterns include: (1) single daily dose paired with tesamorelin, producing one strongly amplified GH pulse; (2) twice-daily dosing (morning with tesamorelin, and at bedtime to align with the natural nocturnal GH pulse); (3) three-times-daily dosing (morning, afternoon, bedtime) for maximum GH exposure across 24 hours. More frequent dosing increases cumulative GH stimulation at the cost of more injections.

Blended injection. Tesamorelin and ipamorelin can be mixed in the same syringe for a single subcutaneous injection when dosed at the same time. Both are reconstituted with bacteriostatic water and are chemically compatible in solution over short periods. Combining them reduces the daily injection burden from two injections to one. Reconstituted blends should be used within the reconstituted stability window of the shorter-stability peptide (typically 14–28 days refrigerated).

Timing considerations. Both peptides are most effective when GH-suppressing factors are minimized. Elevated blood glucose and insulin suppress pituitary GH response to both GHRH and ghrelin stimulation, which is why fasted or semi-fasted dosing (at least 1–2 hours after carbohydrate intake, ideally 30+ minutes before the next meal) produces the largest GH pulse. Pre-bedtime dosing aligns the induced pulse with the natural nocturnal GH peak and maximizes sleep-phase GH exposure.

Published clinical data for the specific tesamorelin + ipamorelin combination is limited — most body composition evidence comes from tesamorelin monotherapy (Phase III), CJC-1295/ipamorelin combinations (smaller studies), and mechanistic reasoning from the known pharmacology. That said, clinical experience and research peptide use consistently report that the stack produces more pronounced results than either peptide alone.

Visceral fat reduction. The tesamorelin monotherapy benchmark is 15–20% VAT reduction over 26 weeks. Stack protocols typically report greater VAT reduction — possibly in the 20–25% range — though this is based on clinical observation rather than controlled trial data. The mechanism is straightforward: larger cumulative GH pulses drive proportionally more visceral adipose lipolysis.

Lean body mass. The amplified GH pulse also produces greater IGF-1 elevation and more sustained anabolic signaling. Lean mass gains on stack protocols typically exceed the 1.3 kg over 26 weeks seen with tesamorelin monotherapy — often approaching 2–3 kg over a comparable timeframe, though again this is clinical observation rather than trial data.

Sleep and recovery. The most consistently reported benefit of the tesamorelin ipamorelin stack is improved sleep quality, particularly when an evening ipamorelin dose is paired with the nocturnal GH window. Recovery from exercise, subjective energy, and perceived training tolerance all tend to improve more quickly on the stack than on tesamorelin alone.

IGF-1 trajectory. Mean IGF-1 elevation on the stack reaches the upper end of the age-adjusted physiologic range more reliably than tesamorelin monotherapy, and maintains this elevation with less day-to-day variability. IGF-1 testing at baseline, 4 weeks, and 12 weeks tracks the biochemical response and allows for dose adjustment if IGF-1 rises beyond the target physiologic range.

See the tesamorelin results timeline for the week-by-week body composition trajectory, which applies directionally to stack protocols with typically larger magnitude of change.

Side effects on the tesamorelin ipamorelin stack are generally the union of the two individual side effect profiles, with the dominant profile being tesamorelin's (since it produces the larger individual GH pulse). Injection site reactions, mild arthralgia, peripheral edema, and occasional mild glucose tolerance changes are all expected possibilities.

Specific stack considerations:

Amplified GH effects. Because the stack produces a larger cumulative GH pulse, the magnitude of GH-related effects is correspondingly greater. This includes both benefits (larger IGF-1 elevation, more visceral fat reduction) and side effects (more pronounced edema in the first weeks, higher risk of glucose intolerance, more pronounced arthralgia). Dose reduction on either peptide is a reasonable response to significant side effects.

Ipamorelin-specific effects. The transient post-injection hunger that some patients notice on ipamorelin monotherapy continues on the stack. This is mechanistically expected from ghrelin receptor activation and is typically mild and self-limiting.

Long-term considerations. The long-term safety profile of the combined stack has not been studied as extensively as tesamorelin monotherapy. Most stack users rely on the established safety data for each peptide individually and on clinical experience suggesting that combined use does not introduce qualitatively new safety signals beyond the individual profiles.

Full individual side effect data is covered in the tesamorelin side effects guide.

The most common GHRH/ghrelin mimetic stack in the research peptide world is actually CJC-1295 + ipamorelin, not tesamorelin + ipamorelin. Both are valid configurations of the same dual-pathway concept. The difference is in the GHRH component.

CJC-1295 without DAC. A shorter-acting GHRH analog with a half-life comparable to or slightly longer than tesamorelin. Mechanistically similar, cheaper, widely available through research peptide suppliers. Lacks tesamorelin's Phase III clinical data.

CJC-1295 with DAC. The extended-release version, with a drug affinity complex that extends the half-life to days or a week. Produces sustained GHRH-R activation rather than pulsatile stimulation, which is a pharmacologically different pattern from tesamorelin's intentionally pulsatile approach. Some researchers prefer the pulsatile pattern (preserving the natural rhythm of GH secretion); others prefer the sustained approach (convenient, once-weekly dosing possible).

Tesamorelin advantage. Stronger clinical evidence, FDA-approved status, well-characterized pharmacokinetics, and proven 15–20% VAT reduction data. Higher cost.

CJC-1295 advantage. Lower cost, wider availability through research channels, and in the DAC version, convenience of infrequent dosing. Less clinical evidence.

For patients whose primary goal is the evidence-based outcome (visceral fat reduction) and who can access and afford tesamorelin, the tesamorelin + ipamorelin stack is the stronger clinical choice. For research-grade or cost-constrained use, CJC-1295 + ipamorelin is a reasonable alternative that activates the same dual-pathway mechanism with similar directional effects.